On 17 February 2016, NeuroTau Inc partner was granted orphan designation (EU/3/16/1614) by the European Commission for tolfenamic acid for the treatment of behavioural variant frontotemporal dementia.
Follow Us:
Welcome to Our Site!
We are a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to improve outcomes in patients sufferings
Our Recent Blogs
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Progressive Supranuclear Palsy (PSP)
Public summary of opinion on orphan designation – Tolfenamic acid for the treatment of progressive supranuclear palsy
On 17 February 2016, NeuroTau partner was granted orphan designation (EU/3/16/1613) by the European Commission for tolfenamic acid for the treatment of progressive supranuclear palsy.
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Frontotemporal Dementia (FTD)
NeuroTau Inc announces listing of its clinical trial “Evaluation of Tolfenamic Acid in Individuals with Progressive Supranuclear Palsy (PSP)” on ClinicalTrials.gov and intention to begin study in Q1/2021
This cancer paper tested various classes of NSAIDS and showed that fenamates have a unique independent mechanism of action that alters the levels of the SP family of transcription factors.
Mefenamic acid shows neuroprotective effects and improves cognitive impairment in vitro and in vivo Alzheimer’s disease models
This manuscript demonstrated the first published role for a protective effect of fenamates in AD models.
The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer’s drugs using multiple platforms
The findings of these studies provide evidence that fenamates can penetrate the brain in sufficient quantities to have an impact on targets therein.
Client Testimonials
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam. Customer
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam.
At vero eos et accusam et justo dolores et ea rebum stet clita kasd gubergren noa takimata sanctus est. Customer
At vero eos et accusam et justo dolores et ea rebum stet clita kasd gubergren noa takimata sanctus est.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore. Customer
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore.
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam. Customer
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam.
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam. Customer
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam.
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam. Customer
Consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt utlabore et dolore magna aliquyam.
Progress bar
Contact Form
Team Member
Nasser Zawia
Founder/CEO
Nasser H. Zawia was a former dean and the inaugural director of the Interdisciplinary Neuroscience Program (INP) at the University of Rhode Island. He played a co-founding role in the formation of the George and Anne Ryan Institute for Neuroscience.
Marwan Sabbagh
Chief Medical Officer
Dr. Sabbagh is the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. Dr Sabbagh has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases.
Daniel Brennan
Chief Business and Operating Officer
Mr. Brennan most recently served as the Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ: CPRX) and Chief Operating Officer at Edge Therapeutics (NASDAQ: EDGE) where he was responsible for pre-commercialization and launch activities of the company’s lead products targeting rare neurological conditions.
Development pipeline
Balanced mix of new substance developments and life cycle management opportunities.
We focus on core competencies and its many years of experience. We thus hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Development pipeline
Balanced mix of new substance developments and life cycle management opportunities.
We focus on core competencies and its many years of experience. We thus hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
© NeuroTau, Inc. 2017 | All Rights Reserved
